Lead drug candidate LB1148 is a phase 3-ready, oral drug with the potential to both reduce abdominal adhesions and help restore bowel function following surgery, two complications that increase the time patients spend in hospitals. LB1148 has pipeline-in-a-product potential, given the array of various complications downstream of digestive enzyme damage that could be addressed by preserving intestinal integrity.
Read More